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FAT1, which encodes a protocadherin, is one of the most frequently mutated genes in 
human cancers1–5. However, the role and the molecular mechanisms by which FAT1 
mutations control tumour initiation and progression are poorly understood. Here, 
using mouse models of skin squamous cell carcinoma and lung tumours, we found 
that deletion of Fat1 accelerates tumour initiation and malignant progression and 
promotes a hybrid epithelial-to-mesenchymal transition (EMT) phenotype. We also 
found this hybrid EMT state in FAT1-mutated human squamous cell carcinomas. Skin 
squamous cell carcinomas in which Fat1 was deleted presented increased tumour 
stemness and spontaneous metastasis. We performed transcriptional and chromatin 
profiling combined with proteomic analyses and mechanistic studies, which revealed 
that loss of function of FAT1 activates a CAMK2–CD44–SRC axis that promotes YAP1 
nuclear translocation and ZEB1 expression that stimulates the mesenchymal state. 
This loss of function also inactivates EZH2, promoting SOX2 expression, which 
sustains the epithelial state. Our comprehensive analysis identified drug resistance 
and vulnerabilities in FAT1-deficient tumours, which have important implications for 
cancer therapy. Our studies reveal that, in mouse and human squamous cell 
carcinoma, loss of function of FAT1 promotes tumour initiation, progression, 
invasiveness, stemness and metastasis through the induction of a hybrid EMT state.
FAT1 is very frequently mutated in a broad range of human cancers—in 
particular, in squamous cell carcinomas (SCCs)1–5. Mutations in FAT1 
have previously been associated with poor clinical outcome and resist-
ance to anti-cancer therapy6. In skin SCCs induced by the chemical car-
cinogen 7,12-dimethylbenz[a]-anthracene (DMBA) in combination with 
12-O-tetradecanoylphorbol-13-acetate (TPA) (hereafter, DMBA/TPA), Fat1 
is mutated in about 20% of cases7, as in human SCCs. Stop–gain mutations 
are very frequently found, which indicates that these mutations result in 
loss of function (LOF) and that FAT1 acts as a tumour-suppressor gene1,4,8. 
Knockdown of FAT1 using short hairpin RNA in human cancer cell lines has 
previously been shown to decrease cell–cell adhesion and promote cell 
migration, whereas contradictory results have been obtained regarding 
the role of FAT1 in regulating EMT in vitro9,10. However, a formal in vivo 
demonstration by a genetic LOF experiment that shows that Fat1 acts as 
a tumour-suppressor gene is lacking. More importantly, the molecular 
mechanisms by which mutations in FAT1 promote tumorigenesis and 
control tumour heterogeneity in vivo are completely unknown.
Fat1 deletion promotes malignant progression
To assess whether Fat1 LOF promotes tumour initiation, we performed 
conditional deletion of Fat1 in the skin epidermis using the constitu-
tive Krt14-cre (Krt14-cre;Fat1flox/flox;Rosa26YFP/+; hereafter referred to as 
Fat1-constitutive knockout (Fat1-cKO)) mouse model. Fat1-cKO mice 
were born at a Mendelian ratio and did not present skin abnormalities 
(Extended Data Fig. 1). Following administration of DMBA/TPA, tumori-
genesis developed more rapidly: the number of benign and malignant 
tumours per mouse was increased in Fat1-cKO mice, which demon-
strates that Fat1 acts a tumour-suppressor gene in DMBA/TPA-induced 
skin SCCs (Extended Data Fig. 2a–f). To assess the role of FAT1 in regu-
lating malignant progression, we performed acute deletion of Fat1 
in benign papillomas using inducible Krt14-creER (Krt14-creER; 
Fat1flox/flox;Rosa26YFP/+). Immunostaining and electron microscopy analy-
ses revealed that after deletion of Fat1, the polarity of the basal cells 
as well as the adherens and tight junctions were rapidly lost, the basal 
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lamina became discontinued, the hemidesmosomes were decreased 
and KRT10 expression—characteristic of benign tumour differentia-
tion—was rapidly lost (Extended Data Fig. 2j–r).
These data demonstrate that Fat1 deletion promotes malignant pro-
gression by controlling cell polarity and adhesion between tumour 
cells, and between tumour cells and the extracellular matrix.
Fat1 deletion promotes a hybrid EMT
The histological differences we observed in benign papillomas per-
sisted in malignant SCCs. Fat1-cKO tumour cells were less cohesive 
and had rounded shapes; most of these tumour cells expressed the 
mesenchymal marker vimentin, which suggest that they underwent 
EMT. Fluorescence-activated cell sorting (FACS) analysis showed that 
Fat1-cKO SCCs contained a large proportion of EPCAM− cells, which 
was very rare in DMBA/TPA-induced SCCs with wild-type Fat1. The EMT 
occurred very early during tumour progression, as EPCAM− tumour 
cells could be detected in papillomas (Fig. 1a–c, Extended Data Fig. 3).
Distinct tumour EMT states—which are characterized by the expres-
sion of different levels of the cell-surface markers EPCAM, CD106, CD61 
and CD51, and represent different stages within the EMT process—have 
recently been recognized11. The majority of the Fat1-cKO EPCAM− EMT 
tumour cells were negative for the CD106, CD61 and CD51 markers or 
expressed CD106 alone; these represent two hybrid EMT subpopu-
lations characterized by the co-expression of epithelial and mesen-
chymal markers in genetically induced skin SCCs11. We performed 
cytospin on FACS-isolated tumour cells, which confirmed that Fat1 
deletion promoted the appearance of hybrid EMT subpopulations 
that co-express epithelial (KRT14) and mesenchymal (vimentin) mark-
ers (Fig. 1c–f). These data demonstrate that a genetic mutation in a 
tumour-suppressor gene can promote the acquisition of a hybrid EMT 
phenotype.
To assess whether Fat1 LOF promotes the acquisition of a hybrid 
EMT phenotype in other models, we combined deletion of Fat1 and 
p53 (also known as Trp53) with KrasG12D expression in different epi-
dermal lineages. Krt14-creER, which targets the interfollicular epider-
mis, induces SCCs with well-differentiated phenotypes without EMT 
features, whereas Lgr5-creER—which targets the hair follicle—induces 
heterogeneous tumours characterized by different degrees of EMT12. 
Similar to what we found in DMBA/TPA-derived SCCs, loss of Fat1 in the 
Krt14-creER;KrasG12D;p53cKO;Fat1cKO;Rosa26YFP/+ mouse model promoted 
the acquisition of a hybrid EMT phenotype, whereas Lgr5-creER-induced 
SCCs—which presented high proportion of EMT phenotypes indepen-
dently of Fat1 deletion—did not further increase EMT features upon Fat1 
LOF. By contrast with the control condition11, most Lgr5-creER Fat1-cKO 
tumour cells continued to express KRT14 and presented signs of squa-
mous differentiation that were visible as keratin pearls (Extended Data 
Fig. 4a–m). These data demonstrate that, in three independent mouse 
models of skin SCC, Fat1 deletion promotes the acquisition of stable 
hybrid EMT phenotypes.
To assess whether the promotion of the tumour hybrid state by Fat1 
deletion is skin-specific or whether it is conserved across different types 
of tumour, we combined Fat1 and p53 deletion with KrasG12D expression 
in the lung epithelia by intratracheal instillation of cre-expressing ade-
novirus. Fat1 deletion considerably increased the number of tumours 
per lung (Extended Data Fig. 4n, o), and these tumours also presented 
signs of hybrid EMT. Whereas KrasG12D expression and p53 deletion 
promoted the onset of adenocarcinomas characterized by expres-
sion of NKX2-1 (also known as TTF1), the simultaneous deletion of 
Fat1 promoted the formation of lung SCCs, which were characterized 
by a decreased expression of NKX2-1 as well as by SOX2 expression 
(Fig. 1g–l). This is consistent with the higher proportion of FAT1 muta-
tions found in lung SCCs relative other types of lung cancer1,2, and sug-
gests that FAT1 mutations could be a driving force for the squamous 
tumour phenotype.
To assess the human relevance of our findings, we performed FAT1 
deletion using CRISPR–Cas9 in the A388 human epithelial SCC cell 
line, which contains wild-type FAT1. Upon FAT1 deletion, cells were less 
cohesive and more rounded, had decreased expression of E-cadherin 
and co-expressed epithelial (KRT14, p63 and SOX2) and mesenchymal 
(vimentin and ZEB1) markers (Fig. 1m), which is reminiscent of the 
EMT hybrid state found in mouse SCCs. By sequencing patient-derived 
xenotransplants of SCCs from different organs, we identified SCCs 
with and without FAT1 LOF mutations. Co-immunostaining of 
pan-cytokeratin and vimentin showed that FAT1-mutated SCCs exhibit 
a much higher EMT hybrid score as compared to SCCs with wild-type 
FAT1 (Fig. 1n, o, Extended Data Fig. 5). These data show that FAT1 muta-
tions promote the acquisition of a hybrid EMT state in human cancers.
FAT1 deletion promotes stemness and metastasis
EMT has previously been associated with an increase in tumour 
stemness11–14. Tumour transplantation assays of Fat1-cKO and wild-type 
EPCAM+ and EPCAM− tumour cells showed that Fat1 LOF was associated 
with a tenfold increase in tumour-propagating cells as compared to 
Fat1 wild type. The histology of the secondary tumours recapitulated 
the histology of the primary tumours (Fig. 2a, b). Tumour stemness is 
also associated with increased clonogenicity in vitro. To validate our 
findings, we assessed the clonogenicity of wild-type and FAT1-knockout 
human SCC cell lines in 3D tumour spheroid assays. FAT1-knockout cell 
lines grew much better than the isogenic wild-type control cell line 
(Fig. 2c, d). Altogether, these data show that FAT1 deletion promotes 
tumour stemness in mouse and human cancers.
The hybrid EMT tumour state has previously been associated with 
the presence of circulating tumour cells and with increased metastatic 
potential upon intravenous injection of tumour cells11. Notably, the 
proportion of the mice presenting lymph node and lung metastases 
and the number of metastases per mouse were increased in Fat1-cKO 
mice (Fig. 2e–h). Intravenous injection of EPCAM+ Fat1-cKO tumour 
cells gave rise to a higher number of lung metastasis as compared to 
tumour cells with wild-type Fat1 (Fig. 2i–l), which demonstrates that 
Fat1 LOF greatly increases spontaneous metastasis and lung coloniza-
tion in skin SCCs, independently of the number of primary tumours or 
the occurrence of EMT. These data demonstrate that Fat1-LOF-induced 
hybrid EMT state promotes metastasis in vivo.
Gene signature of Fat1-mutated tumours
To investigate the molecular mechanisms by which Fat1 LOF promotes 
the hybrid EMT state, we first assessed the transcriptional signature 
of Fat1-mutated tumour cells from mouse skin SCCs. RNA sequencing 
(RNA-seq) revealed that Fat1-cKO EPCAM+ tumour cells presented a 
strong upregulation of many well-known EMT markers—including Vim, 
Snai1, Prrx1, Twist1, Zeb1 or Zeb2—and the expression of these genes was 
further upregulated in EPCAM− Fat1-knockout tumour cells, which sug-
gests that EPCAM+ Fat1-cKO tumour cells are transcriptionally primed 
to undergo EMT. In contrast to EPCAM− tumour cells from Lgr5-creER; 
KrasG12D;p53cKO-derived SCCs that present full EMT, EPCAM− Fat1-cKO 
tumour cells continued to express high levels of several epithelial genes 
(such as Krt14, p63 and Sox2). The transcriptional signature of Fat1-cKO 
tumour cells significantly overlapped with the hybrid EMT signature 
obtained by RNA-seq of CD106−CD61−CD51− hybrid EMT tumour cells 
from Lgr5-creER;KrasG12D;p53cKO SCCs and did not overlap significantly 
with the full EMT signature11 (Fig. 3a, b, Extended Data Fig. 5f, g).
RNA-seq data from EPCAM+ and EPCAM− Fat1-cKO lung cancer cells 
and from CRISPR–Cas9 FAT1-knockout human SCC cells showed that—
in both cases—similar mesenchymal genes (including ZEB1, ZEB2 and 
VIM) were upregulated following deletion of FAT1, uncovering a com-
mon gene signature associated with FAT1 deletion across different 
tumour types and between mouse and human cancers. Importantly, 
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we found that high expression of this common FAT1-mutated signature 
was associated with poor survival in patients with lung SCC (Fig. 3c–e).
YAP1 and SOX2 regulate the hybrid EMT
To define the changes in the chromatin landscape that are respon-
sible for the hybrid EMT state that occurs after deletion of Fat1, we 
performed assay for transposase-accessible chromatin using sequenc-
ing (ATAC-seq) of FACS-isolated wild-type and Fat1-cKO EPCAM+ and 
EPCAM− tumour cells. We identified enhancers within key EMT tran-
scription factors (such as Zeb1, Snail1 or Twist2) and other EMT mark-
ers (for example, Vim or Col6a3) that were more accessible in EPCAM+ 
Fat1-cKO tumour cells as compared to EPCAM+ wild-type cells, which 
potentially accounts for the epigenetic priming of tumour cells to 
undergo EMT upon Fat1 deletion. By performing motif discovery in 
differentially accessible chromatin regions between wild-type and 
Fat1-mutated tumour cells, we identified Ap1 (also known as Jun) and 
Tead transcription-factor motifs as being strongly enriched in the chro-
matin regions that are more open in Fat1-mutated tumour cells that 
also have increased expression of YAP1 (Fig. 3f, Extended Data Fig. 6), 
which suggests that the JUN and FOS family of transcription factors 
cooperates with other transcription factors—including those of the 
TEAD family—that relay the YAP1 pathway to the nucleus to prime the 
Fat1-mutated cancer cells to undergo the EMT in skin SCC in vivo8.
To identify the transcription factors that are responsible for the 
sustained expression of epithelial genes in EPCAM− Fat1-cKO tumour 
cells, we performed motif discovery in the ATAC-seq peaks that were 
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Fig. 1 | LOF of Fat1 promotes hybrid EMT state in mouse skin SCC, mouse 
lung cancer and human SCC. a, Immunostaining for GFP, E-cadherin (E-cad), 
vimentin (VIM) and KRT14 (K14) in EPCAM+ control (wild-type (WT)), EPCAM+ 
Fat1-cKO and EPCAM− Fat1-cKO DMBA/TPA-induced SCCs. Scale bars, 50 μm.  
b, c, FACS analysis (b) and percentage of EPCAM expression (c) in control and 
Fat1-cKO YFP+ skin SCCs. Mean ± s.e.m., two-tailed t-test. TC, tumour cell.  
d, Distribution of YFP+EPCAM− tumour cells in CD106 (also known as VCAM1), 
CD61 (also known as ITGB3) and CD51 (also known as ITGAV) subpopulations in 
Fat1-cKO SCCs. Mean ± s.e.m. TN, EPCAM− triple negative (CD106−CD51−CD61−); 
TP, EPCAM− triple positive (CD106+CD51+CD61+). e, f, Co-immunostaining (e) 
and quantification (f) of KRT14 and vimentin in cytospin of FACS-isolated skin 
SCC tumour cells. Scale bars, 20 μm. n = 90 cells per condition and tumour.  
g, Immunostaining for GFP, KRT7, NKX2-1, KRT5, SOX2, KRT8 and KRT18 
(KRT8/18), and vimentin in Fat1 wild-type and -knockout lung carcinomas. 
Scale bars, 50 μm. h, i, FACS analysis (h) and percentage of EPCAM expression 
(i) in control and Fat1-cKO YFP+ lung tumour cells. Mean ± s.e.m., two-tailed 
t-test. j, Distribution of YFP+EPCAM− tumour cells in CD106/VCAM1, CD61/
ITGB3 and CD51/ITGAV subpopulations in Fat1-cKO lung carcinomas. 
Mean ± s.e.m. k, l, Co-immunostaining (k) and quantification (l) of 
pancytokeratin (pan KRT) and vimentin in cytospin of FACS-isolated lung 
carcinoma tumour cells. Scale bars, 20 μm. n = 70 cells per condition and 
tumour. In l, K denotes pancytokeratin. m, Immunostaining for KRT14 and 
vimentin, E-cadherin, SOX2, TRP63 and ZEB1 in FAT1 wild-type and 
FAT1-knockout (KO) A388 human skin SCC cell line. Scale bars, 50 μm.  
n, o, Representative images (n) and quantification of hybrid EMT score (o) 
(colocalization of pancytokeratin and vimentin) in wild-type and FAT1-mutated 
(MUT) head and neck, and lung, patient-derived xenografts. Scale bars, 50 μm, 
Mean ± s.e.m., two-tailed Mann–Whitney U test.
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tumour cells from fully mesenchymal Lgr5-creER;KrasG12D;p53cKO SCCs. 
We found that Ap1, Sox or Klf motifs were strongly enriched in EPCAM− 
Fat1-cKO cells (Fig. 3g, Extended Data Fig. 6), which suggests that the 
epithelial program of the hybrid EMT state in Fat1-cKO is mediated 
by an AP1–SOX2–KLF transcriptional network. SOX2 is amplified in 
many human SCCs and marks cancer stem cells in skin SCCs15–17, and 
could be responsible for the sustained expression of epithelial genes 
in Fat1-cKO tumour cells.
To functionally validate the bioinformatic predictions, we assessed 
the effect of CRISPR–Cas9-mediated deletion of Yap1 and Taz, or of 
Sox2, on tumour stemness, metastasis and the gene expression program 
of mouse skin SCCs. Both tumour-propagating cell frequency and the 
number of metastasis were reduced upon deletion of Sox2 or of Yap1 and 
Taz in primary EPCAM− cell lines derived from Lgr5-creER;KrasG12D;p53cKO; 
FatcKO SCCs (Fig. 3h, i), which demonstrates that the SOX2 and the YAP1 
and TAZ transcriptional programs are important for the promotion of 
tumour stemness and metastasis downstream of Fat1 deletion. SOX2 or 
YAP1 deletion in the human SCC cell line decreased the tumour growth 
mediated by FAT1 deletion in 3D spheroid assays (Fig. 3j), which dem-
onstrates that SOX2 and YAP1 promote tumour growth downstream 
of FAT1 deletion in human cancer cells. Conversely, the deletion of the 
E-cadherin gene (CDH1) in the same cell line—which induced defects of 
cell adhesion—did not induce SOX2 or ZEB1 expression, or an increase 
in nuclear YAP1. Overexpression of CDH1 in FAT1-knockout cells did not 
decrease the clonogenicity or the expression of mesenchymal genes 
induced by FAT1 deletion (Extended Data Fig. 7a–f), which shows that 
the promotion of tumour stemness or the hybrid EMT phenotype by 
FAT1 deletion is not simply the result of a defect in cell adhesion.
Sox2 deletion in Lgr5-creER;KrasG12D;p53cKO;FatcKO SCCs resulted in the 
loss of epithelial characteristics and a shift from hybrid to complete EMT 
upon subcutaneous transplantation, whereas the deletion of Yap1 and 
Taz promoted an early hybrid EMT state (as shown by immunostaining 
and FACS analysis) (Fig. 3k–m, Extended Data Fig. 7g–i). The RNA-seq 
data from Fat1 and Sox2 knockout further demonstrated a significant 
enrichment in the late EMT signature, marked by an increase of mes-
enchymal markers (for example, Lox and Pdgfra) and a decrease of 
epithelial markers (for example, Cebpa, Krt5 and p63). Instead, the tran-
scriptome of Fat1, Yap1 and Taz triple-knockout SCCs showed significant 
enrichment of the EPCAM+ epithelial and early hybrid EMT signature. 
Many classical canonical target genes of YAP1 and TAZ (for example, 
Ctgf (also known as Ccn2), Amotl2 and Fstl1), as well as EMT genes (for 
example, Vcam1, Thy1 and Pdgfrb), were decreased after Fat1, Yap1 and 
Taz triple knockout as compared to Fat1 knockout (Fig. 3n, o, Extended 
Data Fig. 7j, k and data not shown). Altogether, these data demonstrate 
that SOX2, and YAP1 and TAZ, control distinct transcriptional programs 
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n = 13 mice n = 12 mice
Fig. 2 | Fat1 deletion promotes tumour stemness and metastasis in skin 
SCCs. a, Tumour-propagating cell (TPC) frequency observed upon 
subcutaneous transplantation of limiting dilutions of YFP+EPCAM+ control, 
YFP+EPCAM+ and total YFP+ Fat1-cKO tumour cells using extreme limiting 
dilution analysis. χ2 test. d.f., degrees of freedom. b, Immunostaining for GFP, 
KRT14 and vimentin in the secondary tumours arising after subcutaneous 
transplantation of tumour cells. Scale bars, 50 μm. c, Images showing 
spheroids formed 7 d after plating 4,000 FAT1 wild-type or FAT1-knockout 
human A388 skin SCC cells on an ultra-low adherent plate. d, Quantification of 
cell number in FAT1 wild-type and FAT1-knockout spheroids. Mean + s.e.m., 
two-tailed t-test. e, f, Proportion of mice presenting lymph node (LN) 
metastasis (χ2 test) (e) and number of lymph node metastases per mouse (f) 
(mean ± s.e.m., two-tailed t-test). Mets, metastases. g, h, Proportion of mice 
presenting lung metastasis (χ2 test) (g) and number of lung metastases per 
mouse (h) (mean ± s.e.m., two-tailed t-test). i, Proportion of mice presenting 
lung metastasis 40 d after intravenous injection of 20,000 YFP+EPCAM+ 
tumour cells. χ2 test. j, Mosaic images of immunostaining for YFP of lungs after 
intravenous injection of control and Fat1-cKO tumour cells Scale bars, 1 mm.  
k, Number of metastases per lung arising from the injection of 20,000 
YFP+EPCAM+ Fat1 wild-type and Fat1-cKO tumour cells. Mean ± s.e.m., 
two-tailed t-test.
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Signalling cascades downstream of FAT1
To understand how FAT1 LOF activates SOX2 or YAP1 and TAZ, we per-
formed a phosphoproteomic analysis of wild-type and CRISPR–Cas9 
FAT1-knockout human SCC cells. We identified 288 phosphosites 
that were significantly upregulated and 335 that were significantly 
downregulated in FAT1-knockout tumour cells as compared to FAT1 
wild type. FAT1 LOF induced a decrease in the phosphorylation of 
proteins involved in cell–cell adhesion (such as ZO1 or ZO2), as well 
as of PRKCD, EGFR, ERBB2, MEK1, MEK2, AKT2 or MTOR. In good 
accordance with the phosphoproteomic analysis, MEK1 and MEK2 
were significantly less phosphorylated—and the total levels of EGFR 
and phosphorylated EGFR—were decreased in FAT1-knockout tumour 
cells (Fig. 4a–c, Extended Data Figs. 8, 9). These data suggest that 
EGFR–RAS–RAF–MEK–MAPK and the EGFR–PI3K–AKT–MTOR sig-
nalling pathways are decreased upon FAT1 LOF.
Conversely, FAT1-deficient tumour cells exhibited a strong increase in 
the phosphorylation of the YES tyrosine kinase that belongs to the SRC 
family, as well as of the MAP1B and GJA1 proteins. GJA1 phosphorylation 
promotes GJA1 localization at the plasma membrane and increases the 
formation of functional gap junctions, which has previously been linked 
to increased metastatic capacity18 (Extended Data Fig. 8). These data 
suggest that FAT1 LOF induces a global remodelling of cell–cell adhe-
sions, cell communication and the cytoskeleton, which is associated 
with the acquisition of a hybrid EMT state.
To decipher the signalling cascade that acts downstream of FAT1 LOF, 
we used the PhosphoSitePlus online tool and bibliographic search to 
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Fig. 3 | YAP1 and SOX2 regulate mesenchymal and epithelial states 
downstream of Fat1 deletion. a, b, mRNA expression (RNA-seq) of 
mesenchymal (a) and epithelial (b) genes in mouse skin SCC. Mean + s.e.m. TF, 
transcription factor. c, d, mRNA expression (RNA-seq) of mesenchymal genes 
in mouse lung carcinoma (c) and human SCC cells (d). Mean + s.e.m. e, Overall 
survival of patients with lung SCC, stratified by the expression of the common 
gene signature between mouse skin and lung and human skin FAT1-knockout 
SCC. log-rank Mantel–Cox test. f, g, Immunohistochemistry for YAP1 (f) and 
immunostaining for GFP and SOX2 (g) in wild-type and Fat1-cKO skin SCCs. 
Scale bars, 50 μm. h, i, Tumour-propagating cells (h) and lung metastasis (i) 
following the injection of YFP+EPCAM− Fat1-knockout, Fat1- and Sox2 
double-knockout or Fat1, Yap1 and Taz triple-knockout skin SCC cells. 
Mean ± s.e.m. two-tailed-t-test. NS, not significant. j, Number of cells in 
spheroids formed by FAT1-knockout, FAT1 and YAP1 double-knockout or FAT1 
and SOX2 double-knockout human SCC cells after 7 d. Mean ± s.e.m., two-tailed 
t-test. k–m, YFP+EPCAM− CD106/VCAM1, CD61/ITGB3 and CD51/ITGAV 
subpopulations in SCC after subcutaneous transplantation of Fat1-cKO (k), 
Fat1 and Sox2 double-knockout (l) or Fat1, Yap1 and Taz triple-knockout (m) 
mouse skin SCC cells. Mean ± s.e.m. Scale bars, 50 μm. n, o, mRNA (RNA-seq) 
expression of genes controlled by Sox2 (n) or by Yap1 and Taz (o) in EPCAM− 
Fat1-cKO skin SCC. Mean + s.e.m.
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Ca2+/calmodulin-dependent protein kinase II (CAMK2) was the kinase 
that we found to most frequently act upstream of phosphopeptides 
enriched in FAT1-knockout tumour cells (CD44 on S70619 and GJA1 on 
S328, S325, S306, S330, S364 and S36520). In accordance with the bio-
informatic prediction, western blot analysis showed that CAMK2 was 
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Fig. 4 | Phosphoproteomic analysis identifies the signalling cascades 
downstream of FAT1 deletion. a, Volcano plot showing the fold change and 
statistical significance of each phosphopeptide in wild-type versus 
FAT1-knockout cells (false-discovery rate (FDR) = 0.05, S0 = 1). b–e, Western blot 
showing phosphorylated (p)MEK1 and MEK2 (MEK1/2) and total MEK (b), 
pEGFR and total EGFR (c), pCAMK2 and total CAMK2 (d), and pSRC, total SRC 
and YES (e) in FAT1-knockout and wild-type cells. f, Western blot showing pSRC, 
total SRC and YES in FAT1-knockout cells treated with dimethyl sulfoxide 
(DMSO) or with a CAMK2 inhibitor (CAMK2i). g, h, FACS analysis showing CD44 
expression in wild-type and FAT1-knockout cells (g), and in FAT1-knockout cells 
treated with a CAMK2 inhibitor (h). i, FAT1-knockout cells expressing high 
levels of CD44 were treated with DMSO or a CAMK2 inhibitor. Mean + s.e.m. 
two-tailed-t-test. j, Western blot showing pSRC, total SRC and YES in 
FAT1-knockout and FAT1 and CD44 double-knockout cells. k, Number of cells in 
FAT1-knockout and FAT1 and CD44 double-knockout spheroids. Mean + s.e.m. 
two-tailed-t-test. l, Immunostaining for E-cadherin, CD44, YAP1, ZEB1 and SOX2 
in FAT1 and CD44 double-knockout, and FAT1-knockout, cells treated with 
DMSO, an SRC inhibitor (SRCi) (saracatinib) or a CAMK2 inhibitor. Scale bars, 
50 μm. m–o, Western blot showing the expression of H3K27me3 and total H3 in 
FAT1 wild-type and -knockout cells (m), FAT1-knockout cells treated with a 
CAMK2 inhibitor (n) and in FAT1 wild-type cells treated with DMSO or an  
EZH2 inhibitor (EZH2i) (o). p, q, SOX2 mRNA (quantitative PCR with reverse 
transcription) (p) and protein (western blot) (q) in FAT1 wild-type cells 7 d after 
treatment with an EZH2 inhibitor. Mean ± s.e.m., two-tailed t-test. r, ChIP–qPCR 
of H3K27me3 mark in regions close to the SOX2 transcription start site. Ratio of 
relative enrichment in FAT1 wild-type versus -knockout cells; one sample t-test, 
mean ± s.e.m. s, t, Dose–response curve showing the effect of the EGFR 
inhibitor (ECFRi) afatinib (s) and the SRC inhibitor dasatinib (t) on FAT1 
wild-type and FAT1-knockout cell viability at 48 h. Nonlinear regression log 
(inhibitor) with least-squares fit method. Mean ± s.e.m. u, Summary (n = 3) of 
pIC50 (negative log of half-maximal inhibitor concentration) and s.e.m. for 
different drugs for FAT1 wild-type and FAT1-knockout cells. Two-tailed t-test.  
v, w, Effect of dasatinib and afatinib on FAT1 wild-type (v) and FAT1-knockout 
(w) tumour growth upon subcutaneous transplantation. Mean ± s.e.m., 
two-way analysis of variance. The molecular weight (kDa) is indicated to the 
right of the blots in b–f, j, m–o, q.
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wild type. We further confirmed that SRC and YES also showed high 
levels of expression and phosphorylation upon FAT1 LOF. Immuno-
precipitation of SRC and YES showed that YES was substantially more 
highly expressed and phosphorylated with FAT1 knockout, whereas the 
levels of SRC were comparable between FAT1 wild-type and -knockout 
tumour cells, and SRC phosphorylation was increased after FAT1 knock-
out (Extended Data Fig. 8h). Treatment with a CAMK2 inhibitor (KN93) 
greatly decreased the level of SRC and YES phosphorylation, which 
shows that CAMK2 directly or indirectly phosphorylates YES and SRC 
upon FAT1 LOF (Fig. 4d–f, Extended Data Fig. 8).
CD44 is upregulated during EMT, promoting tumour stemness, 
progression and metastasis21. Previous computational analysis pre-
dicted that an ESRP1–CD44–ZEB1 loop stabilizes the hybrid EMT state 
in human lung cancer cells22. Phosphorylation of CD44 by different 
kinases, including CAMK223, regulates its cellular localization and 
activity. To assess whether CD44 phosphorylation at S706 (which 
is upregulated upon FAT1 LOF) could affect CD44 cellular localiza-
tion, we performed a FACS analysis that revealed increased levels of 
cell-surface CD44 in FAT1-knockout cells, which were significantly 
reduced upon treatment with a CAMK2 inhibitor (Fig. 4g–i). To deter-
mine whether CAMK2 phosphorylates YES and SRC directly or through 
CD4421 signalling in FAT1-knockout cells, we performed CD44 deletion 
using CRISPR–Cas9 in FAT1-knockout cells and found that phospho-
rylation of SRC was decreased upon double knockout of CD44 and 
FAT1 (Fig. 4g–j). These data demonstrate that upon FAT1 LOF, CAMK2 
activates SRC at least partially though CD44. The clonogenicity of FAT1 
and CD44 double-knockout human SCC cells decreased significantly 
in 3D tumour spheroid assays (Fig. 4k), which demonstrates that CD44 
stabilization contributes to the increase in tumour stemness observed 
upon FAT1 LOF.
We further assessed whether the hybrid EMT phenotype could be pro-
moted by CAMK2–CD44–SRC signalling. We found that FAT1 and CD44 
double-knockout and FAT1-knockout cells treated with CAMK2 (KN93) or 
SRC (saracatinib or dasatinib) inhibitors presented a strong decrease in 
nuclear YAP1 and ZEB1 and an increase in expression of E-cadherin, and 
were growing in more-compact epithelial colonies. These results dem-
onstrate that FAT1 LOF activates a CAMK2–CD44–SRC–YAP–ZEB1 axis 
that promotes the expression of a mesenchymal program. We observed a 
decrease in SOX2 expression only in FAT1-knockout tumour cells treated 
with a CAMK2 inhibitor. However, no change in SOX2 expression was 
observed upon inhibition of the CD44–SRC cascade (Fig. 4l).
Phosphoproteomic analysis revealed an increase in the inactivat-
ing phosphorylation of EZH2 at T48724 in FAT1-knockout cells. EZH2 
belongs to the PRC2 complex that methylates H3 at K27, mediating 
transcriptional repression25. This histone mark is remodelled at the 
Sox2 locus during the formation of SCCs15. We hypothesized that EZH2 
inhibition in FAT1-knockout cells could decrease trimethylation of H3 
at K27 (H3K27me3) repressive histone marks, and thus promote the 
expression of SOX2. The global level of H3K27me3 was substantially 
decreased in FAT1-knockout cells, which suggests that EZH2 could 
be less active upon FAT1 LOF. Administration of a CAMK2 inhibitor 
increased the global levels of H3K27me3 in FAT1-knockout cells, con-
sistent with the notion that CAMK2 activation inhibits EZH2 and PRC2 
activity in tumour cells. To further validate this hypothesis, we treated 
FAT1 wild-type cells with an EZH2 inhibitor (GSK343) and observed 
a decrease of H3K27me3 and increase in SOX2 mRNA and protein 
expression after seven days of treatment, which further suggests that 
SOX2 is epigenetically regulated by a FAT1–CAMK2–EZH2-dependent 
mechanism. Chromatin immunoprecipitation with quantitative PCR 
(ChIP–qPCR) demonstrated that H3K27me3 marks around the SOX2 
promoter were significantly reduced upon FAT1 deletion, which pro-
vides support for the notion that FAT1 deletion regulates the expression 
of SOX2 through an epigenetic mechanism (Fig. 4m–r).
As YAP1 and TAZ signalling can be regulated by the stiffness of the 
extracellular matrix26, we assessed the effect of substrate stiffness 
on YAP1 and SOX2 expression. In contrast to FAT1 wild-type cells, 
FAT1-knockout tumour cells exhibited high levels of total and nuclear 
YAP1 expression even on a soft substrate, which demonstrates that 
FAT1 deletion constitutively activates signalling pathways that lead to 
high YAP1 expression; this causes the FAT1-knockout cells to behave—in 
respect to YAP1 nuclear expression—as if the tumour cells were exposed 
to a stiff substrate. No changes in SOX2 expression were observed, 
demonstrating that SOX2 is constitutively activated upon FAT1 LOF 
independently of the extracellular stiffness (Extended Data Fig. 10a–d).
Drug vulnerabilities in FAT1-mutated tumours
To test whether the signalling cascades that change upon FAT1 LOF 
could predict therapeutic resistance and vulnerability of FAT1-mutated 
cancers, we assessed the sensitivity of wild-type and isogenic 
FAT1-knockout human cancer cell lines to the inhibitors of the signal-
ling pathways that we found to be differentially regulated between 
wild-type and FAT1-knockout cells. EGFR inhibitors such as afatinib, 
and MEK inhibitors such as trametinib, are widely used in patients with 
metastatic SCC27,28. FAT1-knockout cells were significantly more resist-
ant to afatinib and trametinib as compared to FAT1 wild-type SCC cells 
in vitro (Fig. 4s–u).
By contrast, FAT1-knockout tumour cells were significantly more 
sensitive to the SRC inhibitors dasatinib and saracatinib and the 
CAMK2 inhibitor KN93 as compared to FAT1 wild-type tumour cells 
(Fig. 4s–u). Administration of afatinib and dasatinib to mice trans-
planted with FAT1 wild-type and -knockout human SCC cell lines showed 
that FAT1 wild-type tumour cells were more sensitive to afatinib and 
FAT1-knockout tumour cells were more sensitive to dasatinib (Fig. 4v, 
w), consistent with the difference in drug sensitivity observed in vitro.
Discussion
Our study reveals that, in mouse models and human cancers, FAT1 
deletion promotes the acquisition of a hybrid EMT state that presents 
increased tumour stemness and metastasis. We identify the epigenetic 
and transcriptional mechanisms that link a loss of cell polarity and cell 
adhesion with the induction of a hybrid EMT phenotype downstream of 
Fat1 deletion. Our comprehensive molecular characterization—includ-
ing transcriptomic, epigenomic and proteomic characterization of 
Fat1 mutants—shows that the hybrid EMT signature is mediated by 
the activation of YAP1 and SOX2, which regulate the co-expression of 
mesenchymal and epithelial transcriptional programs, respectively, in 
cancer cells. We show that the gene signature associated with FAT1 LOF 
is predictive of poor survival in patients with lung cancer. We identify 
the signalling cascades that lead to the activation of YAP1 and SOX2 
downstream of FAT1 LOF. The activation and inhibition of these signal-
ling pathways lead to an increased sensitivity of FAT1-mutated cancer 
cells to CAMK2 and SRC inhibition and to resistance to EGFR and MEK 
inhibition (Extended Data Fig. 10). This study has important implica-
tions for personalized medicine, in the prognosis and treatment of 
the high number of patients with cancer that displays FAT1 mutations.
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Extended Data Fig. 1 | Fat1 LOF does not alter development and skin 
homeostasis. a, Image showing Fat1-cKO mouse and its control littermate.  
b, Table showing the number of control mice and mice with constitutive 
Fat1-cKO in skin epidermis, showing the absence of deviation from Mendelian 
ratio. c, Haematoxylin and eosin staining in control and Fat1-cKO epidermis. 
Scale bar, 50 μm. d, e, Immunostaining for GFP and KRT10, KRT14, E-cadherin 
or ITGB4 in control (d) and Fat1-cKO (e) epidermis. Scale bar, 50 μm.
Article
Extended Data Fig. 2 | See next page for caption.
Extended Data Fig. 2 | Fat1 LOF accelerates DMBA/TPA-induced tumour 
initiation and malignant progression. a, Model allowing constitutive Fat1 
deletion in the skin epidermis and the scheme of DMBA/TPA protocol.  
b, Control and Fat1-cKO littermates 24 weeks after initiation of DMBA/TPA 
treatment. c, d, Time elapsed from the beginning of DMBA/TPA treatment until 
the appearance of the tumour (log-rank Mantel–Cox test) (c) and the number of 
papillomas per mouse (mean ± s.e.m., two-tailed t-test) (d) in control and Fat1-
cKO mice. e, Macroscopic appearance of papilloma and carcinoma. f, Number 
of carcinomas per mouse at 24 weeks after DMBA/TPA in control and Fat1-
knockout mice. Mean ± s.e.m., two-tailed t-test. g, Acute deletion of Fat1 in 
DMBA/TPA-induced papillomas. h, Time elapsed from tamoxifen (tam) 
administration to macroscopic malignant progression from papillomas into 
carcinomas. log-rank Mantel–Cox test. i, Proportion of papillomas that 
progressed to carcinomas in control and Fat1-cKO mice. χ2 test.  
j, k, Immunostaining for KRT14, KRT10 and LAM5 in control ( j) and Fat1-cKO 
papillomas (k) 0, 2, 4 and 8 weeks after tamoxifen administration. Scale bar, 
50 μm. l, Haematoxylin and eosin and immunostaining for YFP, E-cadherin,  
ZO-1 or CLDN1 in control and Fat1-cKO papillomas. Scale bar, 50 μm. m–o, Electron  
microscopy images showing polarity (Scale bars, 2 μm (control papilloma), 
5 μm (Fat1-cKO papilloma)) (m), cell–cell adhesion (scale bar, 0.2 μm) (n) or 
desmosomes (scale bar, 0.2 μm) (o) in Fat1-cKO and wild-type papillomas. Red 
lines indicate interface between tumour cells and stroma. Blue arrowheads, 
desmosomes. Red arrowheads, tight and adherens junctions. p, Width of  
the desmosomes measured in nm in control and Fat1-cKO papillomas. 
Mean ± s.e.m., two-tailed t-test. q, Electron microscopy (scale bars, 0.2 μm 
(control), 5 μm (Fat1-cKO)) and immunostaining for KRT14 and LAM5  
(scale bar, 50 μm) of control and Fat1-cKO papillomas. Blue arrowheads, 
hemidesmosomes. Red arrowheads, basal lamina in control papillomas and 
discontinued basal lamina in Fat1-cKO papillomas. Black arrowheads show 
fenestration of basal lamina in Fat1-cKO papillomas. r, Number of 
hemidesmosomes per 1 μm. Mean ± s.e.m., two-tailed t-test).
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Extended Data Fig. 3 | EMT in papillomas and gating strategy for FACS 
analysis and cell sorting of the tumour subpopulations. a, Percentage of 
EPCAM+YFP+ tumour cells in control and Fat1-cKO papillomas. Mean ± s.e.m., 
two-tailed t-test. b, c, mRNA (qPCR) expression of epithelial (b) and 
mesenchymal (c) genes in EPCAM+ and EPCAM− control and Fat1-cKO 
papillomas. Mean + s.e.m. d, FACS plots showing the gating strategy used to 
FACS-isolate or to analyse the proportion of YFP+EPCAM+ and EPCAM− tumour 
cells from DMBA/TPA-induced K14-cre;Fat1cKO;Rosa26YFP/+ carcinomas and 
papillomas, Lgr5-creER;KRasG12D;p53cKO;Fat1cKO;Rosa26YFP/+ or K14-creER;KRasG12D
;p53cKO;Fat1cKO;Rosa26YFP/+ skin SCCs and KrasG12D;p53cKO;Fat1cKO;Rosa26YFP/+ lung 
carcinomas. e, FACS plots showing the gating strategy to define the six 
subpopulations of EPCAM− tumour cells: EPCAM−CD106−CD51−CD61− (triple 
negative), EPCAM−CD106+CD51−CD61−, EPCAM−CD106−CD51+CD61−, 
EPCAM−CD106+CD51+CD61−, EPCAM−CD106−CD51+CD61+ and 
EPCAM−CD106+CD51+CD61+ (triple positive) populations.
Extended Data Fig. 4 | See next page for caption.
Article
Extended Data Fig. 4 | Fat1 LOF promotes hybrid EMT state in a genetic 
model of skin SCC. a, Mouse model of skin SCC allowing YFP and KrasG12D 
expression as well as p53 and Fat1 deletion preferentially in the interfollicular 
epidermis (IFE) using Krt14-creER. b, Percentage of EPCAM+ tumour cells in 
control and Fat1-cKO SCCs. Mean ± s.e.m., two-tailed t-test. c, Graph showing 
the distribution of the different EPCAM− tumour cell subpopulations on the 
basis of the expression of CD106/VCAM1, CD61/ITGB3 and CD51/ITGAV in  
Fat1-cKO tumours. Mean ± s.e.m. d, Haematoxylin and eosin staining,  
showing representative control and Fat1-cKO tumours. Scale bar, 50 μm.  
e, f, Immunostaining for GFP, KRT14 or vimentin in representative control (e) 
and Fat1-cKO tumour (f). Scale bar, 50 μm. g, Mouse model of skin SCC allowing 
the expression of YFP and KrasG12D as well as p53 and Fat1 deletion preferentially 
in the hair follicle lineage using Lgr5-creER. h, Percentage of EPCAM+ tumour 
cells in the control and Fat1-cKO tumours. Mean ± s.e.m., two-tailed t-test.  
i, Graph showing the distribution of the different EPCAM− tumour cell 
subpopulations on the basis of the expression of CD106/VCAM1, CD61/ITGB3 
and CD51/ITGAV in Fat1-cKO tumours. Mean ± s.e.m. j, Haematoxylin and eosin 
staining, showing a representative Fat1 wild-type and Fat1-cKO tumour. Scale 
bar, 50 μm. k, l, Immunostaining for KRT14 and vimentin showing the absence 
of keratin pearls in representative EPCAM− control SCC (k) and the presence of 
keratin pearls in representative EPCAM− Fat1-cKO SCC (l). White arrowheads 
indicate keratin pearls. Scale bar, 100 μm. m, Dot plot showing the number of 
keratin pearls quantified per field at magnification 20×. n = 5 fields quantified 
per sample, mean ± s.e.m., two-tailed t-test. n, Mouse model allowing YFP and 
KrasG12D expression as well as p53 and Fat1 deletion in lung epithelial cells using 
intratracheal instillation of Ad5CMVCre virus. o, Immunofluorescence image 
showing the YFP+ lung tumours 10 weeks after intratracheal instillation of 
Ad5CMVCre virus in Fat1 wild-type and Fat1-cKO mice. Scale bar, 1 mm.
Extended Data Fig. 5 | See next page for caption.
Article
Extended Data Fig. 5 | Mutations in FAT1 promotes hybrid EMT state in 
human cancers. a, Schematic representing the method of analysing the co-
expression of pan-cytokeratin and vimentin using immunohistochemistry of 
patient-derived xenografts that present (or not) mutations in FAT1, and the 
definition of hybrid EMT score. b, Table summarizing the samples of patient-
derived xenografts on which whole-exome sequencing was performed, and 
detailed information on the mutations: codon, amino acid change, the exon 
containing the mutation, the allelic frequency, the type of mutations and the 
bioinformatic prediction of the effect of the mutation on the function of the 
protein using three bioinformatic algorithms (SIFT, Memo and PolyPhen).  
c, Heat map showing the copy number variation profile of FAT1 genomic region 
in the patient-derived xenograft samples included in the analysis of hybrid EMT 
score. The colour code corresponds to the quantified copy number and the 
genomic coordinate (reference genome hg19) of bin set for quantification. The 
FAT1 gene is marked on each vertical edge. d, e, Box plot showing the 
distribution of the common mRNA signature (mouse skin and lung Fat1-cKO 
SCCs and human FAT1-knockout SCC cell line) compared to FAT1 mutation 
status in human lung SCC (TCGA database; for the analysis, only high-impact 
mutations in >20% of variant allele frequency were considered) (d) and FAT1 
copy number variation status in human lung SCC (TCGA database) (e). 
Boundaries of the box indicate the first and third quartiles of the FAT1 RNA 
signature value. The bold horizontal line indicates the median and the two 
external horizontal lines shows the minimum and maximum values. The dots 
represent all data points. Differences between the two groups are assessed 
using a two-sided Wilcoxon rank-sum test. f, g, Venn diagram of the genes 
upregulated in the EPCAM+ Fat1-cKO skin SCC and upregulated in LGR5 EPCAM+ 
versus triple-negative hybrid EMT tumour cells (f) or in triple-negative versus 
EPCAM+ cells (g). Two-sided hypergeometric test.
Extended Data Fig. 6 | See next page for caption.
Article
Extended Data Fig. 6 | EPCAM+ Fat1-cKO tumour cells are epigenetically 
primed to undergo EMT, whereas EPCAM− Fat1-cKO sustain the expression 
of epithelial program. a, ATAC-seq profiles of the chromatin regulatory 
regions of mesenchymal genes closed in control EPCAM+ tumour cells and 
opened in EPCAM+ Fat1-cKO tumour cells, showing epigenetic priming of 
EPCAM+ Fat1-cKO tumour cells to undergo EMT. b, ATAC-seq profiles of the 
chromatin regulatory regions of mesenchymal genes with open chromatin 
regions only in EMT EPCAM− tumour cells. c, Transcription factor motifs 
enriched in the ATAC-seq peaks upregulated between the EPCAM+ Fat1-cKO 
and EPCAM+ control tumour cells as determined by Homer. Cumulative 
hypergeometric distributions. White boxes show core transcription factors; 
boxes highlighted in green show epithelial transcription factors; and boxes 
highlighted in orange show EMT transcription factors. d, Transcription factor 
motifs enriched in the ATAC-seq peaks that are upregulated between the 
EPCAM− Fat1-cKO and EPCAM− control tumour cells as determined by Homer 
analysis. Cumulative hypergeometric distributions. White boxes show core 
transcription factors; boxes highlighted in green show epithelial transcription 
factors; boxes highlighted in orange show EMT transcription factors; and 
boxes highlighted in grey show other transcription factors. e, ATAC-seq of the 
chromatin regulatory regions of epithelial genes with open chromatin regions 
in EPCAM− Fat1-cKO tumour cells as compared to EPCAM− tumour cells from 
LGR5-derived SCCs, showing the sustained opening of epithelial enhancers in 
EPCAM− Fat1-cKO tumour cells. f, ATAC-seq of the chromatin regulatory 
regions of epithelial genes that are closed upon EMT, irrespective of Fat1 
deletion. g, Immunostaining for GFP and AP2G, KLF4, SOX2, p63, GRHL2 or 
ZEB1 in EPCAM+ and EPCAM− control and Fat1-cKO DMBA/TPA skin SCCs.  
Scale bar, 50 μm.
Extended Data Fig. 7 | Loss of cell adhesion is not sufficient to induce the 
hybrid EMT phenotype. a, Images showing spheroids formed 7 d after plating 
4,000 FAT1 wild-type or FAT1 wild-type, CDH1-knockout human A388 skin SCC 
cells on an ultra-low adherent plate. b, Bar chart showing the quantification by 
FACS of the number of cells in FAT1 wild-type, and FAT1 wild-type and CDH1- 
knockout, spheroids. Mean + s.e.m., two-tailed t-test. c, Immunostaining for 
E-cadherin, YAP1, ZEB1 and SOX2 in FAT1 wild-type, and FAT1 wild-type and 
CDH1-knockout, tumour cells. Scale bar, 50 μm. d, Images showing spheroids 
formed 7 d after plating 4,000 FAT1-knockout or FAT1-knockout and 
CDH1-overexpressing human A388 skin SCC cells on an ultra-low attachment 
plate. e, Bar chart showing the quantification by FACS of the number of cells in 
FAT1-knockout or FAT1-knockout and CDH1-overexpressing spheroids. 
Mean + s.e.m., two-tailed t-test. f, Immunostaining for E-cadherin, YAP1, ZEB1 
and SOX2 in FAT1-knockout or FAT1-knockout and CDH1-overexpressing 
tumour cells. Scale bar, 50 μm. g–i, Immunostaining of K14 and vimentin after 
subcutaneous transplantation of Fat1-cKO (g), Fat1 and Sox2 double-knockout 
(h) or Fat1, Yap1 and Taz triple-knockout (i) mouse skin SCC cells. Mean ± s.e.m. 
Scale bars, 50 μm. j, k, Venn diagram of the genes upregulated in EPCAM− 
Fat1-cKO skin SCC upon Sox2 deletion ( j) or upon Yap1 and Taz deletion (k), and 
upregulated genes in hybrid EMT triple-negative cells versus late EMT 
triple-positive cells (early hybrid EMT signature) and in triple-positive versus 
EPCAM+ cells (late EMT signature). Two-sided hypergeometric test.
Article
Extended Data Fig. 8 | See next page for caption.
Extended Data Fig. 8 | Phosphoproteomic analysis reveals signalling 
cascades downstream of FAT1 LOF. a, Table showing kinases that are 
significantly more phosphorylated in FAT1 wild-type cells as compared to FAT1-
knockout cells. t-test, FDR = 0.05, S0 = 1. b, Bar chart showing the kinases that 
are predicted to phosphorylate phosphosites significantly enriched in FAT1 
wild-type tumour cells. c, Table showing kinases that are significantly more 
phosphorylated in FAT1-knockout cells as compared to FAT1 wild-type cells.  
t-test, FDR = 0.05, S0 = 1. d, Bar chart showing the kinases that are predicted to 
phosphorylate phosphosites that are significantly enriched in FAT1-knockout 
tumour cells. e, Table showing the sites in FAT1-knockout cells predicted to be 
phosphorylated by CAMK2. f, g, Western blot showing pEGFR and EGFR (f) or 
pMEK and MEK (g) in Fat1 wild-type and Fat1-knockout Lgr5-creER;KrasG12D; 
p53cKO;Fat1fl/fl;RYFP mouse skin SCC cells. h, Western blot showing the 
expression levels of pSRC, total SRC and YES on the input of wild-type and FAT1-
knockout cells, and upon immunoprecipitation of SRC and YES (n = 4). The 
apparent molecular weight reference in kDa is indicated close to f–h.
Article
Extended Data Fig. 9 | Full scan of western blot membranes. a–k, Images 
showing full scan of western blot membranes displayed in Fig. 4. Each panel 
indicates the figure and the panel to which the full membrane image belongs. 
Molecular weight size standards are indicated on each membrane. In all the 
experiments the controls (β-actin) were run on the same gel as the samples.
Extended Data Fig. 10 | Increase in YAP1 and SOX2 signalling downstream of 
FAT1 LOF is independent of the stiffness of the substrate. a, Immunostaining  
for YAP1 in FAT1 wild-type and FAT1-knockout human SCC cells upon increasing 
stiffness conditions. Scale bar, 50 μm. b, Quantification of YAP1 expression on 
the basis of fluorescence intensity in FAT1 wild-type and FAT1-knockout cells in 
different stiffness conditions. Mean + s.e.m. c, Quantification of YAP1 nuclear/
cytoplasmic ratio on the basis of fluorescence intensity in FAT1 wild-type and 
FAT1-knockout cells in different stiffness conditions. Mean + s.e.m.  
d, Immunostaining for SOX2 in FAT1 wild-type and FAT1-knockout human  
SCC cells in increasing stiffness conditions. Scale bar, 50 μm e, Model of the 
signalling pathways that are activated or repressed in FAT1-knockout cells to 
induce a hybrid EMT state and to predict a differential effect on the response to 
therapy.
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Life Sciences Reporting Summary
Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life 
science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list 
items might not apply to an individual manuscript, but all fields must be completed for clarity. 
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research 
policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist. 
    Experimental design
1.   Sample size
Describe how sample size was determined. Samples size for each experiment is indicated in the figures or corresponding figure 
legends. The sample size was chosen based on previous experience in the lab, for 
each experiment to yield high power to detect specific effects. The previous 
experiences refers to: the data on the frequency of appearance of tumors and 
survival in DMBA/TPA and genetic models of skin SCC, tumor cellular and molecular 
heterogeneity of the different tumor types, the frequency of metastasis, the 
frequency of secondary tumors upon subcutaneous transplantation and the 
heterogeneity of the secondary tumors, tumor propagating cell frequency, etc 
(Pastushenko Nature 2018, Latil Cell Stem Cell 2017, Beck Cell Stem Cell 2015, 
Boumahdi Nature 2014, Revenco Cell Rep 2019, Lapouge EMBO J 2012).  No 
statistical methods were used to predetermine sample size. 
2.   Data exclusions
Describe any data exclusions. No data were excluded from the analysis
3.   Replication
Describe whether the experimental findings were 
reliably reproduced.
All the experiments were performed in at least 3 biologically independent 
replicates. All replicates reported in the manuscript and on which statistics are 
based are biological replicates. No technical replicates were used to calculate 
statistics. All attempts at replication of the results were successful.
4.   Randomization
Describe how samples/organisms/participants were 
allocated into experimental groups.
For in vivo studies on primary mouse models, animals were chosen based on 
correct genotypes: requiring 2 (K14Cre/RYFP, Fat1/RYFP, K14CreER/Fat1), 3 
(K14Cre/Fat1/RYFP), 4 (Lgr5CreER/Kras/p53/RYFP, K14CreER/Kras/p53/RYFP and 
Kras/p53/Fat1/RYFP) or 5 correct alleles (Lgr5CreER/Kras/p53/Fat1/RYFP or 
K14CreER/Kras/p53/Fat1/RYFP).  
K14Cre and K14CreER mice were treated with DMBA/TPA at the age of 6-8 weeks 
after virth and the mice developed tumors in 4-10 months. K14CreER/Kras/p53 
mice were induced with Tamoxifen at a age 28-35 days after birth, and the mice 
developed tumours in 2-3 months, thus minimizing the difference in age of 
different animals used. Kras/p53/Fat1/RYFP mice were treated with intratracheal 
instillation of AdeCRE virus at the age of 6-12 weeks. 
Sex-specific differences were minimized by including similar numbers of male and 
female animals. Each experiment contained animals from at least 3 different litters. 
In the subcutaneous or intravenous grafting experiments we used NOD/Scid/Il2 
mice of similar age and both female and male.  
For experiments involving cell culture no allocation in groups was needed. For the 
drug screening in vitro both FAT1 WT and FAT1 KO cells were treated with all the 
drugs, so no allocation in groups or randomization was required.  
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5.   Blinding
Describe whether the investigators were blinded to 
group allocation during data collection and/or analysis.
Investigators were  blinded to mouse genotypes during experiments, for 
performing sample analysis, imaging and quantification.  
For experiments with cell lines the researchers were blinded to cell line genotypes 
or treatment conditions for analysis, imaging and quantification. 
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
6.   Statistical parameters 
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the 
Methods section if additional space is needed). 
n/a Confirmed
The exact sample size ( ) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same 
sample was measured repeatedly
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one- or two-sided (note: only common tests should be described solely by name; more 
complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g.  values) given as exact values whenever possible and with confidence intervals noted
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
   Software
Policy information about availability of computer code
7. Software
Describe the software used to analyze the data in this 
study. 
The Chi square and t-test were performed using Prism (version 8). The RNA-
sequencing data were analyzed using STAR software (2.4.2a). Peak calling was 
performed by macs (version 2.1.0.20151222). Peaks were associated to genes with 
GREAT software (4.0.4). The data were analyzed using R software (3.2.3).  
Exome sequencing analysis: bedtools (Version 2.27.0) and ANNOVAR (v2013Jun21). 
Flow cytometry: FACS ARIA III (for FACS sorting) and FACSDiva software (for FACS 
data analysis). 
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made 
available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub).  guidance for 
providing algorithms and software for publication provides further information on this topic.
   Materials and reagents
Policy information about availability of materials
8.   Materials availability
Indicate whether there are restrictions on availability of 
unique materials or if these materials are only available 
for distribution by a for-profit company.
Raw data from RNA-seq, ATAC-seq, Whole Exome Sequencing and low coverage 
Whole Genome Sequencing have been deposited to a public database under the 
following codes: GSE158502 (mouse RNA-seq), GSE158501 (human RNA-seq), 
GSE158500 (ATACseq), GSE158503 (WES) and GSE158505 (low-cogerave WGS) . All 
materials are readily available from the authors or from standard commercial 
sources. There are no restrictions on availability of the materials used in the study.   
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9.   Antibodies
Describe the antibodies used and how they were validated 
for use in the system under study (i.e. assay and species).
For FACS analysis and sorting the following antibodies were used:   
CD51 (rat clone RMV-7, Biolegend Cat#104106, dilution 1:50), BV421-conjugated 
anti-CD61 (Armenian hamster, clone 2C9.G2, BD Bioscience Cat#553345, dilution 
1:50), biotin-conjugated anti-CD106 (rat, clone 429 (MVCAM.A), BD Bioscience 
Cat#553331, dilution 1:50), BV711-conjugated anti-Epcam (rat clone G8.8, BD 
Bioscience Cat#563134, dilution 1:100), PerCPCy5.5 conjugated anti-CD45 (rat, 
clone 30-F11, BD Bioscience Cat#550994, dilution 1:100) and PerCPCy5.5 
conjugated anti-CD31 (rat, clone MEC 13.3, BD Bioscience Cat#562861, dilution 
1:100), APC conjugated anti-CD44 (rat, clone IM7, Biolegend, Cat#103011, 1:100) 
 
For Immunofluorescence and Immunohistochemistry the following antibodies 
were used: 
Primary antibodies: Anti-GFP (goat polyclonal, Abcam Cat#ab6673, 1:400), anti-K14 
(chicken polyclonal, Thermo Fisher Scientific Cat#MA5-11599, 1:1000), anti-K10 
(rabbit, polyclonal, Covance/IMITEC Cat#PRB-159P-0100, 1:1000), anti-Krt5 (rabbit 
polyclonal, BioLegend Cat#905501/Formerly Covance Antibody Product Cat# 
PRB-160P, 1:1000), Anti-Krt7 (Rabbit monoclonal antibody, clone EPR1619Y, 
Abcam Ct#ab68459, 1:200), anti-Itgb4 (rat, clone 346-11A, BD Cat#553745, 1:200), 
anti-Vimentin (rabbit, clone ERP3776, Abcam Cat#ab92547, 1:500), anti-E-
Cadherin (rat, clone ECCD-2, Invitrogen Cat#13-1900, 1:200), anti-YAP1 (for IF 
rabbit, polyclonal, Proteintech Cat#13584-1-AP; for IHC rabbit, polyclonal, 
SantaCruz Cat#sc-15407, 1:50), anti-Sox2 (rabbit, clone  ERP3131, Abcam 
Cat#ab92494, 1:200), anti-Grhl2 (rabbit, polyclonal, Sigma, Cat#HPA004820, 1:50), 
Anti-Klf4 (rabbit, polyclonal, Abcam Cat#ab129473, 1:50), anti-p63 (rabbit, 
polyclonal, Abcam Cat#ab97865, 1:50), anti-AP2g (rabbit, polyclonal, Abcam 
Cat#ab220872, 1:50), anti-Cldn1 (rabbit, polyclonal, ThermoFisher Cat#51-9000, 
1:50), anti-Zo1 (mouse, clone ZO1-1A12, ThermoFisher Cat#33-9100, 1:50),  anti-
Zeb1 (rabbit, polyclonal Bethyl/IMITEC Cat#IHC-00419, 1:200), anti-CD44-APC (rat, 
clone IM7, Biolegend, Cat#103011, 1:50) 
The following secondary antibodies were used: anti-rabbit, anti-rat, anti-goat, anti-
chicken, anti-mouse conjugated to rhodamine Red-X (Jackson ImmunoResearch - 
Cat.#711-295-152; 712-295-153; 705-295-147; 703-295-155; 715-295-151), Alexa 
Fluor 647 (Jakson ImmunoResearch - Cat.#711-605-152; 712-605-153 ; 
705-605-147; 703-605-155; 715-605-150) or to Alexa Fluor-A488 (Molecular 
Probes - Cat.#A21206; A21208; A11055; A11039; A21202). 
For immunohistochemistry the VECTASTAIN ABC-HRP Kit, Peroxidase (Rabbit IgG) - 
(PK-4001) has been used (Vector Laboratories).  
 
For Western Blot the following antibodies were used:  
Anti-phospho-CAMK2 (Rabbit, 1/133, Cell Signaling, clone D21E4, cat#12716), anti-
phospho-SCR Tyr416 (Rabbit, 1:3000, Cell Signaling, clone D49G4, Cat#6943), anti-
H3K27Me3 Lys27 (Rabbit, 1:3000, Millipore, Cat#17-622), anti-phospho-MEK1/
MEK2 Ser218, SER222, Ser226 (Rabbit, 1:1000, Invitrogen, Cat#44-454G), anti-
phospho-EGFR Y1197 (Rat, 1:500, R&D, MAB8058), anti–CAMK2 (pan) (Rabbit, 
1/125, Cell Signaling, clone D11A10, cat#4436), anti-SRC (Rabbit, 1:1000, Cell 
Signaling, clone32G6, Cat#2123) or anti-H3 (Rabbit, 1:6000, Abcam, Cat#ab1791), 
anti–MEK1/MEK2 (Rabbit, 1:1000, Invitrogen, Cat#PA5-31917), anti-EGFR (Rabbit, 
1:1000, Cell Signaling, clone D38B1, Cat#4267), anti-YES (Rabbit, 1:1000, Cell 
Signaling, clone D9P3E, Cat#65890) and anti– -actin (1:2000, Abcam, Cat#ab8227). 
Anti-rabbit or anti-rat immunoglobulin G (IgG) conjugated with horseradish 
peroxidase (HRP) (1:3000 or 1:5000; Healthcare) was used as the secondary 
antibody. The antibodies are commercially available and were validated by the 
provider. We used the protocols and recommendations of the manufacturer only 
on validated species (mouse or human).  
 
For ChIP rabbit monoclonal antibody for H3K27me3 (C36B11 Rabbit mAb, #9733 
Cell Signaling Technologies) was used.  
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10. Eukaryotic cell lines
a.  State the source of each eukaryotic cell line used. A388 (human skin SCC cell), primary mouse skin SCC cell lines (derived from Lgr5/
Kras/p53 Fat1 WT and Fat1cKO skin SCC). 
b.  Describe the method of cell line authentication used. None of the cell lines have been authenticated.
c.  Report whether the cell lines were tested for 
mycoplasma contamination.
The cell lines were not tested for mycoplasma contamination.
d.  If any of the cell lines used are listed in the database 
of commonly misidentified cell lines maintained by 
ICLAC, provide a scientific rationale for their use.
None of the cell lines used are listed in the database of commonly misidentified 
cell lines maintained by ICLAC. 
    Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
11. Description of research animals
Provide details on animals and/or animal-derived 
materials used in the study.
All the animals used were grown in mixed background.  
K14Cre/RYFP, Fat1/RYFP, K14CreER/Fat1, K14Cre/Fat1/RYFP were treated 3 times 
with DMBA 6-8 weeks after birth and after received treatment with TPA twice a 
week until the tumors appeared.  
Lgr5CreER/Kras/p53/RYFP, K14CreER/Kras/p53/RYFP, Lgr5CreER/Kras/p53/Fat1/
RYFP and K14CreER/Kras/p53/Fat1/RYFP mice were induced with Tamoxifen at 
28-35 days after birth.  
The mice were sacrificed if tumour reached the size allowed by ethical protocol or 
if mice presented signs of distress or weight loss >20% was observed. The average 
weight of the mice used was 35g (range from 22 to 48g).  
For grafting experiments NOD/SCID/Il2R  mice were used with age ranging from 4 
to 8 weeks. Both male and female mice were used for these experiments. The 
weight of these mice was in average 29 g (ranging from 21 to 37g). 
For qPCR, ATAC-qPCR, RNA-sequencing, ATAC-sequencing and grafting 
experiments (subcutaneous and intravenous grafting into immunodeficient mice) 
subpopulations of cancer cells isolated from primary tumors were used. Sections of 
prefixed frozen or paraffin embedded primary tumors, organs or skin were used 
for immunostaining.  
NOD/SCID/Il2R  null mice were used for transplantation and metastasis assays (by 
performing subcutaneous and intravenous grafting of tumor cells) 
For lung cancer experiments Kras/p53/RYFP and Kras/p53/RYFP/Fat1KO mice were 
treated with intratracheal instillation of AdenoCre. The mice were followed up 
daily and were sacrificed if any signs of respiratory distress, weight loss or 
deterioration of general condition were detected.  
The housing conditions of all animals were strictly following the ethical regulations. 
The room temperature ranged from 20 and 25°C. The relative ambient humidity at 
the level of mouse cages was 55 per cent +/-15. Each cage was provided with food, 
water and two types of nesting material. Semi-natural light cycle of 12:12 was 
used. 
Policy information about studies involving human research participants
12. Description of human research participants
Describe the covariate-relevant population 
characteristics of the human research participants.
Samples of human cancers were included. All the cases for which the Whole Exome 
Sequencing data (that allow identification of FAT1 mutation) were available were 
included in the study. All the patients included in the Patient Derived Xenograft 
platform gave their consent and the study was approved by the all relevant 
institutions. The researchers involved in this work did not have access to the 
clinical data (such as age or gender). All the samples received were asigned by the 
clinican or surgeon responsible for patient care a unique code. 
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Flow Cytometry Reporting Summary
 Form fields will expand as needed. Please do not leave fields blank.
    Data presentation
For all flow cytometry data, confirm that:
1.  The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
2.  The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of 
identical markers).
3.  All plots are contour plots with outliers or pseudocolor plots.
4.  A numerical value for number of cells or percentage (with statistics) is provided.
    Methodological details
5.   Describe the sample preparation. Skin tumors from DMBA/TPA treated mice, Lgr5CreER/Kras/p53/Fat1cKO/
RYFP and K14CreER/Kras/p53/Fat1cKO/RYFP or lung tumors from Kras/
p53/Fat1cKO/RYFP mice were dissected, minced and digested in 
Collagenase type I (Sigma) at 3.5 mg/ml during 1 hour at 37ºC on a rocking 
plate protected from light. Collagenase activity was blocked with by the 
addition of EDTA (5mM) and then the cells were rinsed in PBS 
supplemented with 2% FBS and the cell suspensions were filtered through 
a 70um cell strainers (BD).  
6.   Identify the instrument used for data collection. FACSAria and LSRFortessa (BD Bioscience)
7.   Describe the software used to collect and analyze 
the flow cytometry data.
FACSDiva and FACSAria Software (BD Bioscience)
8.   Describe the abundance of the relevant cell 
populations within post-sort fractions.
The proportion of YFP+ tumor cells in Lin- population varied from 20 to 
95%. The proportion of tumor cell subpopulations within YFP+ tumor cells 
varied depending on the tumor type and between individual tumors. 
9.   Describe the gating strategy used. Living cells were selected by forward scatter, side scatter, doublets 
discrimination and by 7AAD dye exclusion. Tumor cell subpopulations were 
selected based on the expression of YFP and the exclusion of CD45 and 
CD31. 
 Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
